Loading
companiesCompany
Latent Labs
Founded by an AlphaFold co-developer to make protein design programmable; released Latent-X in 2025.
Overview
Latent Labs, based in London, was founded by an AlphaFold co-developer to make protein design programmable, and released Latent-X in 2025. Latent-X generates de novo binders, including macrocycles and mini-binders, with reported high wet-lab hit rates, and is available through a web platform. OnCo links it to de novo designed protein binders. Whether designed macrocycles and mini-binders can reach intracellular cancer targets that antibodies cannot is the open question. The de novo protein binder page carries the wider field.
Similar pages
- CompanyCradle
Shares De novo designed protein binders, AI-driven drug & target discovery and the tags ai, protein-design.
- CompanyProfluent
Shares De novo designed protein binders, AI-driven drug & target discovery and the tags ai, protein-design.
- CompanyIambic Therapeutics
Shares AI-driven drug & target discovery and the tag ai.
- CompanyGenesis Molecular AI (formerly Genesis Therapeutics)
Shares AI-driven drug & target discovery and the tag ai.
- CompanyChai Discovery
Shares the tags ai, protein-design.
- CompanyEvolutionaryScale
Shares the tags ai, protein-design.
- InstitutionInstitute for Protein Design (University of Washington)
Shares the tags ai, protein-design.
- CompanyLila Sciences
Shares AI-driven drug & target discovery and the tag ai.